Effects of neoadjuvant chemotherapy on the quantitative expression of P-gp, LRP, MRP, GST-π in NSCLC and its clinical significance

Chinese Journal of Lung Cancer

Volumn 10, Issue 5, 2007, Pages 398-405

  Xiang, Fenggang ^a   Yu, Wenjuan ^a   Shen, Yi ^a   Wu, Cuijiao ^a   Wang, Yuewei ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Drug resistance protein; Neoadjuvant chemotherapy; Non small cell lung cancer; Quantitation; Tissue chip

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EXCISION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OPTICAL DENSITY; POSTOPERATIVE CARE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

EID: 35948955940     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay I, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005,55(2):74-108.
2. Zhi XY, Zhang Y, Xu QS. The effect of neoadjuvant chemoradiotherapy on stage III non-small cell lung carcinoma before surgery. ChinJ Tuberc Respir Dis, 2006,29(1):60.
3. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and III a non-small-cell lung cancer. J Clin Oncol, 2002,20(1):247-253.
4. Comment in: J Clin Oncol, 2002,20(10):2603-2604; author reply 2605.
5. Hao J, Wang Y, Li QC, et al. MRP expression in non-small cell lung cancer and normal lung tissues and its prognostic significance. Chin J Lung Cancer, 2005,8(1):32-36.
6. Tang XP, Mao BY, Yu DY, et al. Expression of cyclin D-1, P16 and its correlation with clinicopathological characteristics and prognosis in medulloblastoma. Chin J Neurosurgery, 2004,20(5):377-380.
7. Rigas JR, Lara PN Jr. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer, 2005,50S2:S17-S24.
8. Pohl G, Krajnik G, Malayeri R, et al. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer. Lung Cancer, 2006,54(1):63-67.
9. Muraoka M, Oka T, Akamine S, et al, Postoperative complications of pulmonary resection after platinum-based induction chemotherapy for primary lung cancer. Surg Today, 2003,33(1):1-6.
10. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 2004,78(6):1903-1909.
11. Chen J, Qian GS, Huang GJ, et al. Advances in multidrug resistance mechanisms in lung cancer. Chin Oncol, 2002,12(3):273-276.
12. van der Pol MA, Broxterman HJ, Pater JM, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica, 2003,88(2):134-147.
13. Sutovsky P, Manandhar G, Laurincik J, et al. Expression and proteasomal degradation of the major vault protein (MVP) in mammalian oocytes and zygotes. Reproduction, 2005,129(3):269-282.
14. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol, 2002, 55(5):332-339.
15. Findlay VJ, Townsend DM, Saavedra JE. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol Pharmacol, 2004,65(5):1070-1079.
16. Rybarova S, Hajdukova M, Hodorova I, et al. Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma, 2004,51(3):169-174.
17. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg, 2003,125(4):938-944.
18. Miyatake K, Gemba K, Ueoka H, et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res, 2003,23(3C):2829-2836.
19. Pesic M, Markovic JZ, Jankovic D, et al. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother, 2006,18(1):66-73.
20. Belpomme D, Gauthier S, Pujade-Lauraine E, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol, 2000,11(11):1471-1476.